Insilico Medicine secures Takeda collaboration to advance AI-designed drug candidates
Discover how Takeda’s $600 million Insilico Medicine collaboration could reshape AI drug discovery, candidate design and clinical translation.
Pharma & Biotech
Pharma & Biotech
Why Insilico’s $2.5bn SK Biopharmaceuticals deal could reshape AI drug discovery
Find out how Insilico and SK Biopharmaceuticals are using AI to target neuroimmune CNS disorders in a $2.5B drug discovery pact.
Pharma & Biotech
Xeris wins key Keveyis patent allowance, but will it really slow generic pressure?
Find out how Xeris’ Keveyis patent allowance could reshape rare disease exclusivity, generic pressure and investor sentiment.
Pharma & Biotech
Why Johnson & Johnson is paying $1bn for Firefly Bio’s cancer drug platform
Johnson & Johnson is chasing the next cancer drug platform. Firefly Bio adds promise, but clinical proof remains the real test.
Pharma & Biotech
Why T-CURX’s Pantherna acquisition could matter for the future of cell therapy manufacturing
T-CURX and Pantherna are combining CAR-T, mRNA and LNP platforms. Europe’s in vivo cell therapy race just became more serious.
Pharma & Biotech
How EOM Pharmaceutical Holdings is positioning EOM613 as a potential multi-cytokine therapy for cancer cachexia
Find out how EOM613 could reshape cancer cachexia treatment as EOM Pharmaceutical Holdings advances its FDA-cleared Phase 2a study.
Pharma & Biotech
Concept Life Sciences expands drug discovery model as OpenBench brings AI-enabled screening scale
Biotechs need faster hits with less upfront risk. Concept Life Sciences and OpenBench are testing whether success-based discovery can deliver.
Pharma & Biotech
Why Assembly Biosciences’ liver disease strategy now extends far beyond viral hepatitis
Assembly Biosciences is expanding ABI-6250 beyond HDV into PBC and PSC. Find out why NTCP inhibition is gaining industry attention.
Pharma & Biotech
Can IVF-inspired skincare move AVL beyond beauty marketing into longevity science?
Beauty wants biotech credibility. AVL’s IVF-inspired skincare push tests whether longevity science can reshape premium skincare.
Pharma & Biotech
What AbCellera’s upcoming ABCL635 Phase 1 data could reveal about the future of menopause treatment
AbCellera will reveal Phase 1 ABCL635 data on May 11. Read why this menopause drug update could matter for investors and women’s health watchers.